Accreditation Information

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)
This application-based activity is approved for 2.0 contact hours (0.2 CEUs) of continuing pharmacy education credit (UAN 0245-0000-17-005-L01-P).

Nursing (ANCC)
This activity is designated for 2.0 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Participants will be provided with instructions for receiving credit through Creative Educational Concepts’ web portal, CE Spectrum, at the live activity.

ONCC/ILNA Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. OCN®, AOCNP®, and AOCNS® nurses may apply 1.75 points in Treatment Modalities and 0.25 points in Symptom Management categories.

ONCC/ILNA Disclaimer
ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

Needs Statement

Immune checkpoint inhibition (ICI) targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 pathway (PD-1/PD-L1) has dramatically improved the care of patients with many advanced malignancies.1 Although ICI targeting CTLA-4 and PD-1/PD-L1 shows a broad range of activity, there are cancer types that seem to be resistant to such therapy. Therefore, identifying biomarkers that predict response to therapy and the occurrence of immune-mediated adverse reactions is crucial to ensure optimal patient outcomes.2 Based on the ever-expanding knowledge about the mechanism of action of various cancer immunotherapy approaches, including ICI targeting CTLA-4 and PD-1/PD-L1, it is clear that combination therapies are the next logical step to improve response rates, increase durations of responses, and potentially increase cure rates.1-3

This engaging, interactive symposium will feature clinically relevant debates between experts in the field of solid tumor immunotherapy within the context of patient case-based scenarios. After an update on the current state of immune checkpoint inhibitors in selected types of solid tumors, experts will debate the emerging concepts involved in immunotherapy combinations and the role of prognostic and predictive biomarkers of response. Attendees will participate in the discourse by voting for a “point” or “counterpoint” position on audience response keypads prior to and after evidence-based faculty member discussions.

1Ott PA, et al. J Immunother Cancer. 2017. 2Topalian SL. Nat Rev Cancer. 2016. 3Mahoney KM, et al. Nat Rev Drug Discov. 2015.


1. Differentiate the mechanism of action and safety and efficacy of current and emerging immune checkpoint inhibitors used in selected types of solid tumors.

2. Appraise the rationale and latest data for combined immune checkpoint blockade in selected types of solid tumors.

3. Evaluate signs and symptoms of the immune-mediated adverse reactions associated with immune checkpoint blockade and strategies members of the healthcare team can employ to anticipate and effectively manage them.

4. Assess utility of PD-L1 expression and other immune variables as prognostic and predictive biomarkers of response to immune checkpoint inhibitors used in selected types of solid tumors.

Target Audience

This activity is targeted towards clinical oncologists and oncology specialty pharmacists and nurses attending the 2017 ASCO Annual Meeting who are involved in selecting immunotherapy regimens and monitoring patients undergoing treatment with immunotherapy agents.

Faculty Disclosure

Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Vanessa Carranza, PharmD – has no relevant financial relationships to disclose in relation to the content of this activity.

Joan B. Fowler, PharmD, BCPP – has no relevant financial relationships to disclose in relation to the content of this activity.


Joaquim Bellmunt, MD, PhD – has disclosed that he is a consultant for Genentech, Merck, Novartis, Pfizer, and Sanofi and receives grant/research support from Novartis and Sanofi.

Robert L. Ferris, MD, PhD – has disclosed that he is a consultant for Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Lilly, Merck, and Pfizer. He also receives grant/research support from AstraZeneca/MedImmune, Bristol-Myers Squibb, Merck, and Venti Rx.

Naiyer Rizvi, MD – has disclosed that he is a consultant for Abbvie, AstraZeneca, Bristol-Myers Squibb, Lilly, Merck, Novartis, Pfizer, Regeneron, and Roche, and is a shareholder/co-founder of Gritstone Oncology.

Jeffrey S. Weber, MD, PhD – has disclosed that he is a consultant for Alkermes, AstraZeneca, Bristol-Myers Squibb, EMD Serono, Genentech, GlaxoSmithKline, Merck, Nektar, and Novartis; his institution receives grant/research support from Mirati for his lab; and he is a major stock shareholder for Altro and CytoMx.